Zymergen subsidiary files Chapter 11; Ginkgo to acquire IP assets as stalking horse bidder

Ginkgo Bioworks Holdings, Inc.

Zymergen Inc., a wholly-owned subsidiary of Ginkgo, filed voluntary Chapter 11 petitions on October 3, 2023 in Delaware.
Neither Ginkgo nor its other subsidiaries filed for bankruptcy; Ginkgo remains well capitalized with $1.1B cash as of Q2 2023.
Ginkgo entered an asset purchase agreement as stalking horse bidder to acquire exclusive rights to substantially all Zymergen IP assets.
Bid includes $5M cash and assumption of up to $77M in future liabilities (lease, employee compensation and severance).
Existing non-exclusive license for Zymergen's databases, automation, and software remains unaffected by the bankruptcy process.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.